Tech Company Financing Transactions

Lysosomal Therapeutics Funding Round

Lysosomal Therapeutics, operating out of Cambridge, scored $20 million in investment from Atlas Venture, Hatteras Venture Partners and Lilly Ventures.

Transaction Overview

Company Name
Lysosomal Therapeutics
Announced On
2/3/2015
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series A
Investors

Atlas Venture (Bruce Booth)

Hatteras Venture Partners (Clay Thorp)

Lilly Ventures (Steven Hall)

Orion Equity Partners

Partners Innovation Fund (Reza Halse)

Roche Venture Fund (Carole Nuechterlein)

Sanofi-Genzyme BioVentures (Bernard Davitian)

Proceeds Purpose
The proceeds will fund ongoing compound optimization and preclinical development of a glucocerebrosidase (GCase) lysosomal enzyme activator candidate for the treatment of Parkinson's disease. In addition, the funding will support a biomarker initiative, for which LTI has previously received grant funding from The Michael J. Fox Foundation for Parkinson's Research.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
19 Blackstone St.
Cambridge, MA 02139
USA
Phone
(617) 714-9620
Website
www.lysosomaltx.com
Email Address
[email protected]
Overview
LTI's unique approach to discovering new drugs for neurodegenerative diseases is based on research performed in the lab of Dr. Dimitri Krainc, one of the company's founders, at Massachusetts General Hospital (MGH), a founding member of Partners HealthCare and an affiliate of Harvard Medical School.
Profile
Lysosomal Therapeutics LinkedIn Company Profile
Social Media
Lysosomal Therapeutics Company Twitter Account
Company News
Lysosomal Therapeutics News
Facebook
Lysosomal Therapeutics on Facebook
YouTube
Lysosomal Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kees Been
  Kees Been LinkedIn Profile  Kees Been Twitter Account  Kees Been News  Kees Been on Facebook
Chief Financial Officer
Daniel Geffken
  Daniel Geffken LinkedIn Profile  Daniel Geffken Twitter Account  Daniel Geffken News  Daniel Geffken on Facebook
Chief Marketing Officer
Dana Hilt
  Dana Hilt LinkedIn Profile  Dana Hilt Twitter Account  Dana Hilt News  Dana Hilt on Facebook
Chief Scientific Officer
Peter Lansbury
  Peter Lansbury LinkedIn Profile  Peter Lansbury Twitter Account  Peter Lansbury News  Peter Lansbury on Facebook
Vice President
Valerie Cullen
  Valerie Cullen LinkedIn Profile  Valerie Cullen Twitter Account  Valerie Cullen News  Valerie Cullen on Facebook
VP - Bus. Development
Darren Braccia
  Darren Braccia LinkedIn Profile  Darren Braccia Twitter Account  Darren Braccia News  Darren Braccia on Facebook
VP - Bus. Development
Renato Skerlj
  Renato Skerlj LinkedIn Profile  Renato Skerlj Twitter Account  Renato Skerlj News  Renato Skerlj on Facebook
VP - Bus. Development
Andrew Sonderfan
  Andrew Sonderfan LinkedIn Profile  Andrew Sonderfan Twitter Account  Andrew Sonderfan News  Andrew Sonderfan on Facebook

 

 

Browse more venture capital transactions:

Prev: 2/3/2015: eRelevance venture capital transaction
Next: 2/3/2015: SoFi venture capital transaction

 

Share this article

 

About Our Venture Capital Transactions Database

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.